Kooperativer Bibliotheksverbund

In: Annals of Pharmacotherapy, SAGE Publications, Vol. 27, No. 10 ( 1993-10), p. 1223-1230

Abstract: To introduce readers to a new low-molecular-weight heparin (LMWH) product, enoxaparin. The chemistry, pharmacology, pharmacodynamics, clinical efficacy in thromboembolic prophylaxis following surgery, and adverse effects are reviewed. DATA SOURCES: A MEDLINE search of the English-language literature was used to identify relevant literature. STUDY SELECTION: A focus was placed on human clinical studies with well-accepted measures of antithrombotic efficacy endpoints, i.e., venography and ultrasonography. Emphasis was on pharmacologic and pharmacokinetic studies conducted in humans. DATA EXTRACTION: Most data were extracted from double-blind, controlled clinical studies. Other study designs were accepted if the results were believed to be significant. Pharmacology and pharmacokinetic data were selected from studies with exceptional design conducted in humans. DATA SYNTHESIS: Enoxaparin is a polysaccharide chain produced by the depolymerization of heparin. In comparison with heparin, which has an average molecular weight of 12 000–15 000 daltons, the average molecular weight of enoxaparin is approximately 4500 daltons. Enoxaparin does not form a complex with antithrombin III and thrombin as extensively as does heparin; however, the anti-X a activity of enoxaparin is similar. The significance of this fact is an enhancement of antithrombotic activity and clinical efficacy. Trials comparing enoxaparin with other thromboembolic prophylaxis techniques are ongoing. CONCLUSIONS: Thromboembolism remains one of the major complications of all surgical procedures. Attempts have been made throughout the last century to develop the most effective means to prevent this complication. Clinical studies performed throughout the world have shown that enoxaparin is superior or equivalent to other antithrombotic agents, including heparin, in preventing the formation of venous thromboembolism. In addition, enoxaparin appears to possess an equivalent or lower incidence of bleeding complications when compared with heparin prophylaxis. Enoxaparin is expected to be joined by other LMWH products in the future. As a result, the methods of providing effective prophylaxis against thromboembolic complications is expected to change in the coming years.

Type of Medium: Online Resource

ISSN: 1060-0280 , 1542-6270

URL: Article

DOI: 10.1177/106002809302701013

Language: English

Publisher: SAGE Publications

Publication Date: 1993

detail.hit.zdb_id: 2053518-1

SSG: 15,3

In: Thrombosis and Haemostasis, Georg Thieme Verlag KG, Vol. 120, No. 03 ( 2020-03), p. 515-524

Abstract: Patients with renal impairment are at higher risk of thrombosis and bleeding than those with normal renal function. The optimal rivaroxaban dose for thromboprophylaxis in acutely ill medical patients with renal impairment is unknown. MARINER and MAGELLAN were multicenter, randomized clinical trials of rivaroxaban in acutely ill medical patients. Efficacy and safety outcomes in patients with renal impairment in MARINER (7.5 mg once daily) were compared with those in patients with normal renal function in MARINER (10 mg once daily) and in a subpopulation of MAGELLAN that excluded patients at high risk for bleeding at baseline (10 mg once daily). Compared with enoxaparin/placebo in the MAGELLAN subpopulation, the relative risk (RR) of symptomatic venous thromboembolism (VTE) and VTE-related death with rivaroxaban 10 mg in patients with renal impairment (RR = 0.62; 95% confidence interval [CI] 0.27–1.44) was similar to that in those with normal renal function (RR = 0.78; 95% CI 0.44–1.40), while in MARINER, the 7.5 mg dose did not reduce the risk in patients with renal impairment (hazard ratio = 1.00; 95% CI 0.52–1.92). Major bleeding with rivaroxaban 10 mg once daily was higher in patients with renal impairment than in those with normal renal function in MAGELLAN (1.54% vs. 0.98%) and in the MAGELLAN subpopulation (0.94% vs. 0.61%). At a dose of 10 mg once daily, rivaroxaban is effective for thromboprophylaxis in acutely ill medical patients with impaired or normal renal function. The safety of this regimen is enhanced without loss of efficacy by excluding patients at high risk for bleeding, but not by using a reduced-dose strategy. Trial Registration ClinicalTrials.gov identifiers: NCT00571649 for the MAGELLAN trial, NCT02111564 for the MARINER trial.

Type of Medium: Online Resource

ISSN: 0340-6245 , 2567-689X

URL: Article

DOI: 10.1055/s-0039-1701009

Language: English

Publisher: Georg Thieme Verlag KG

Publication Date: 2020

In: New England Journal of Medicine, Massachusetts Medical Society, Vol. 379, No. 12 ( 2018-09-20), p. 1118-1127

Type of Medium: Online Resource

ISSN: 0028-4793 , 1533-4406

URL: Article

DOI: 10.1056/NEJMoa1805090

Language: English

Publisher: Massachusetts Medical Society

Publication Date: 2018

detail.hit.zdb_id: 1468837-2

In: TH Open, Georg Thieme Verlag KG, Vol. 06, No. 04 ( 2022-10), p. e304-e308

Abstract: This post hoc subgroup analysis examined efficacy and safety outcomes with extended thromboprophylaxis rivaroxaban compared with in-hospital enoxaparin in 2,078 patients from the MAGELLAN study who had a hospitalization for heart failure or a history of heart failure and a lower risk of bleeding. A significant 36% reduction in the composite endpoint of asymptomatic proximal deep vein thrombosis (DVT) in the lower extremity, symptomatic DVT in the lower extremity (proximal or distal), symptomatic nonfatal pulmonary embolism, and venous thromboembolism-related death was observed with rivaroxaban. Major bleeding was low in both groups and not significantly increased with rivaroxaban.

Type of Medium: Online Resource

ISSN: 2512-9465

URL: Article

DOI: 10.1055/a-1926-2489

Language: English

Publisher: Georg Thieme Verlag KG

Publication Date: 2022

detail.hit.zdb_id: 2893939-6

In: Journal of the American Heart Association, Ovid Technologies (Wolters Kluwer Health), Vol. 10, No. 5 ( 2021-03-02)

Abstract: Asymptomatic proximal deep vein thrombosis (DVT) is an end point frequently used to evaluate the efficacy of anticoagulant thromboprophylaxis in medical patients. Recently, the clinical relevance of asymptomatic DVT has been challenged. Methods and Results The objective of this study was to evaluate the relationship between asymptomatic proximal DVT and all‐cause mortality (ACM) using a cohort analysis of a randomized trial for the prevention of venous thromboembolism (VTE) in acutely ill medical patients. Patients who received at least 1 dose of study drug and had an adequate compression ultrasound examination of the legs on either day 10 or day 35 were categorized into 1 of 3 cohorts: no VTE, asymptomatic proximal DVT, or symptomatic DVT. Cox proportional hazards model, with adjustment for significant independent predictors of mortality, were used to compare the incidences of ACM. Of the 7036 patients, 6776 had no VTE, 236 had asymptomatic DVT, and 24 had symptomatic VTE. The incidence of ACM was 4.8% in patients without VTE. Both asymptomatic proximal DVT (mortality, 11.4%; hazard ratio [HR], 2.31; 95% CI, 1.52–3.51; P 〈 0.0001) and symptomatic VTE (mortality, 29.2%; HR, 9.42; 95% CI, 4.18–21.20; P 〈 0.0001) were independently associated with significant increases in ACM. The analysis was post hoc, and ultrasound results were not available for all patients. Adjustment for baseline variables significantly associated with ACM may not fully compensate for differences. Conclusions Asymptomatic proximal DVT is associated with higher ACM than no VTE and remains a relevant end point to evaluate the efficacy of anticoagulant thromboprophylaxis in medical patients. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT00571649.

Type of Medium: Online Resource

ISSN: 2047-9980

URL: Article

DOI: 10.1161/JAHA.120.019459

Language: English

Publisher: Ovid Technologies (Wolters Kluwer Health)

Publication Date: 2021

detail.hit.zdb_id: 2653953-6

In: Journal of the American College of Cardiology, Elsevier BV, Vol. 75, No. 25 ( 2020-06), p. 3140-3147

Type of Medium: Online Resource

ISSN: 0735-1097

URL: Article

DOI: 10.1016/j.jacc.2020.04.071

Language: English

Publisher: Elsevier BV

Publication Date: 2020

detail.hit.zdb_id: 1468327-1

In: Clinical and Applied Thrombosis/Hemostasis, SAGE Publications, Vol. 25 ( 2019-01-01), p. 107602961988602-

Abstract: Acutely ill medical patients are at risk of venous thromboembolism (VTE) and VTE-related mortality during hospitalization and posthospital discharge, but widespread adoption of extended thromboprophylaxis has not occurred. We analyzed a subpopulation within the MAGELLAN study of extended thromboprophylaxis with rivaroxaban to reevaluate the benefit risk profile. We identified 5 risk factors for major and fatal bleeding after a clinical analysis of the MAGELLAN study and analyzed efficacy and safety with these patients excluded (n = 1551). Risk factors included: active cancer, dual antiplatelet therapy at baseline, bronchiectasis/pulmonary cavitation, gastroduodenal ulcer, or bleeding within 3 months before randomization. We evaluated efficacy, safety, and benefit risk using clinically comparable endpoints in the subpopulation. At day 10, rivaroxaban was noninferior to enoxaparin (relative risk [RR] = 0.82, 95% confidence interval [CI] = 0.58-1.15) and at day 35 rivaroxaban was significantly better than enoxaparin/placebo (RR = 0.68, 95% CI = 0.53-0.88) in reducing VTE and VTE-related death. Major bleeding was reduced at day 10 (RR = 2.18, 95% CI = 1.07-4.44 vs 1.19, 95% CI = 0.54-2.65) and at day 35 (2.87, 95% CI = 1.60-5.15 vs 1.48, 95% CI = 0.77-2.84) for MAGELLAN versus this subpopulation, respectively. The benefit risk profile was favorable in this subpopulation treated for 35 days, with the number needed to treat ranging from 55 to 481 and number needed to harm from 455 to 1067 for all pairwise evaluations. Five exclusionary criteria defined a subpopulation of acutely ill medical patients with a positive benefit risk profile for in-hospital and extended thromboprophylaxis with rivaroxaban.

Type of Medium: Online Resource

ISSN: 1076-0296 , 1938-2723

URL: Article

DOI: 10.1177/1076029619886022

Language: English

Publisher: SAGE Publications

Publication Date: 2019

detail.hit.zdb_id: 2230591-9

In: Clinical Orthopaedics and Related Research, Ovid Technologies (Wolters Kluwer Health), Vol. 299 ( 1994-02), p. 203???208-

Type of Medium: Online Resource

ISSN: 0009-921X

URL: Article

DOI: 10.1097/00003086-199402000-00028

Language: English

Publisher: Ovid Technologies (Wolters Kluwer Health)

Publication Date: 1994

detail.hit.zdb_id: 2018318-5

In: Blood, American Society of Hematology, Vol. 134, No. Supplement_1 ( 2019-11-13), p. 3671-3671

Abstract: Background: Acutely ill medical patients with a history of cancer are at risk of venous thromboembolic events (VTE) in hospital and after discharge. Rivaroxaban was evaluated for VTE prevention in acutely ill medical patients in two randomized clinical trials of extended thromboprophylaxis with rivaroxaban. MAGELLAN (NCT00571649) included patients with active cancer undergoing treatment as well as those with only a history of cancer while the MARINER study (NCT02111564) only included patients with a history of cancer but not active cancer. In MAGELLAN treatment began in hospital (rivaroxaban 10mg QD for 35±4 days vs enoxaparin for 10±4 days followed by placebo), whereas in MARINER, treatment began at discharge (rivaroxaban 10mg QD or 7.5mg QD for those with baseline creatinine clearance 30- & lt;50ml/min vs placebo) for 45 days. In this post hoc subgroup analysis, we compared rivaroxaban versus enoxaparin/placebo (MAGELLAN) or placebo (MARINER) for primary efficacy and key safety outcomes in acutely ill medical patients with only a history of cancer compared to those with no history of cancer. Methods: MAGELLAN and MARINER patients with a history of cancer or cancer in remission but without active cancer undergoing treatment were identified and compared to the subgroup of patients with no history of cancer. Relevant baseline demographics and cancer characteristics were summarized. The primary efficacy outcome was the composite of asymptomatic proximal deep vein thrombosis (DVT), symptomatic VTE and VTE-related death at Day 35 in the modified intention to treat population in MAGELLAN and the composite of symptomatic VTE and VTE-related death up to Day 45 in the intention to treat population in MARINER. The key safety outcome analyzed for both studies was the incidence of clinically relevant bleeding (the composite of ISTH major or non-major clinically relevant bleeding) on treatment + 2 days in randomized subjects who took at least one dose of study drug. Results: In MAGELLAN in the subgroup with a history of cancer, the most frequent reason for hospitalization was an acute infectious disease (61%). In the history of cancer subgroup, the primary efficacy outcome occurred in 8/203 (3.9%) patients on rivaroxaban and in 16/192 (8.3%) patients on enoxaparin/placebo (RR=0.45; 95%CI 0.19, 1.03) whereas in the subgroup with no cancer, it occurred in 95/2467 (3.85%) in patients on rivaroxaban and in 133/2562 (5.19%) in those on enoxaparin/placebo (RR=0.74; 95%CI 0.57, 0.96). Clinically relevant bleeding was increased with rivaroxaban to a similar degree in both subgroups in MAGELLAN. There was no fatal bleeding in patients with history of cancer (Table). In MARINER in the subgroup with a history of cancer, the most frequent reason for hospitalization was heart failure (36%). In the history of cancer subgroup, the primary efficacy outcome occurred in 5/488 (1.02%) in patients in the rivaroxaban group and in 7/533 (1.31%) in patients in the placebo group (HR=0.76; 95%CI 0.24, 2.40) while in those without cancer, it occurred in 45/5519 (0.82%) patients in the rivaroxaban group and in 59/5479 (1.08%) in the placebo group (HR=0.76; 95%CI 0.51,1.11). Clinically relevant bleeding was increased with rivaroxaban to a similar degree in both subgroups in MARINER. There was no fatal bleeding in patients with history of cancer (Table). In both studies, major bleeding was similar in both treatment groups in the subgroup with a history of cancer. Conclusion: VTE was generally more frequent in patients with a history of cancer than those without it. In MAGELLAN, rivaroxaban appears more effective compared with enoxaparin/placebo in reducing the primary composite efficacy outcome in the subgroup with a history of cancer than those without cancer, whereas in MARINER, the reduction in symptomatic VTE and VTE-related death with rivaroxaban was similar in both subgroups. Although clinically relevant bleeding was increased in both studies, major bleeding was similar in those with a history of cancer in both studies and no fatal bleeding events were observed in the history of cancer subgroup in either study. Altogether, these data suggest a generally favorable benefit risk profile for extended thromboprophylaxis with rivaroxaban in acutely ill medical patients with a history of cancer. Disclosures Spyropoulos: Janssen R & D, LLC: Consultancy; ATLAS (Colorado Prevention Center): Consultancy; Bayer Healthcare: Consultancy; Portola: Consultancy; Boehringer Ingelheim: Consultancy, Research Funding; Daiichi Sankyo: Consultancy. Lipardi:Janssen Research and Develompent: Employment, Equity Ownership. Cohen:Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Portola: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; ACI Clinical: Consultancy; Boehringer-Ingelheim: Consultancy, Speakers Bureau; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; CSL Behring: Consultancy; Takeda: Consultancy; GLG: Consultancy; Leo Pharma: Consultancy; Boston Scientific: Consultancy; TRN: Consultancy; UK Government Health Select Committee: Other: advised the UK Government Health Select Committee, the all-party working group on thrombosis, the Department of Health, and the NHS, on the prevention of VTE; Navigant: Consultancy; GlaxoSmithKline: Consultancy, Speakers Bureau; McKinsey: Consultancy; Medscape: Consultancy, Speakers Bureau; Temasek Capital: Consultancy; Lifeblood: Other: advisor to Lifeblood: the thrombosis charity and is the founder of the European educational charity the Coalition to Prevent Venous Thromboembolism; Guidepoint Global: Consultancy; ONO: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Johnson and Johnson: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy; Aspen: Consultancy, Speakers Bureau. Vučković:Janssen Research & Development, LLC: Consultancy. Xu:Janssen R & D, LLC: Employment, Equity Ownership. Lu:Janssen R & D, LLC: Employment, Equity Ownership. Spiro:Bayer U.S. LLC: Employment, Equity Ownership. Barnathan:Janssen Research and Development LLC: Employment, Equity Ownership. Raskob:Tetherex: Consultancy; Portola: Consultancy; Bayer Healthcare: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Boehringer Ingelheim: Consultancy; Daiichi Sankyo: Consultancy, Honoraria; Anthos: Consultancy; Eli Lilly: Consultancy; Novartis: Consultancy; Janssen R & D, LLC: Consultancy, Honoraria; BMS: Consultancy, Honoraria. OffLabel Disclosure: Rivaroxaban is a Factor Xa inhibitor. It is currently under review by FDA for approval as thromboprophylaxis in acutely ill medical patients at risk for venous thromboembolism.

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2019-122945

Language: English

Publisher: American Society of Hematology

Publication Date: 2019

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7

In: Blood, American Society of Hematology, Vol. 134, No. Supplement_1 ( 2019-11-13), p. 163-163

Abstract: Background: Asymptomatic proximal deep-vein thrombosis (ASxDVT) is an efficacy endpoint that has been used for several decades in clinical trials evaluating thromboprophylaxis with anticoagulants. Previous studies have suggested the finding of ASxDVT on routine ultrasonography is associated with increased subsequent all-cause mortality (ACM). We evaluated the relationship between ASxDVT and subsequent ACM using the data from the MAGELLAN study (NCT00571649), a randomized clinical trial that evaluated rivaroxaban compared with enoxaparin followed by placebo for the prevention of venous thromboembolism (VTE) in acutely ill medical patients in which routine compression ultrasonography was performed at Day 10 and at Day 35. Patients were followed up through 90 days. Methods: A post hoc analysis was performed using patients who received at least one dose of study drug and had an adequate ultrasound result at Day 10 or Day 35 (modified intent-to-treat population, mITT). Patients were categorized into one of three mutually exclusive groups: (1) those without VTE; (2) those with symptomatic VTE (SxVTE); and (3) those with an ASxDVT. If patients had an ASxDVT followed by an SxVTE event, they were categorized into the ASxDVT group. Baseline covariates (age, sex, race, BMI, diabetes, creatinine clearance, heart failure, acute ischemic stroke, acute infectious disease, inflammatory disease, acute respiratory insufficiency, history of VTE, history of cancer, history of anemia and assigned treatment group) were tested for association with ACM (p & lt;0.05). A Cox proportional hazards model, which included the VTE variable and significant baseline covariates (history of cancer, heart failure, acute ischemic stroke, inflammatory disease, acute respiratory insufficiency, BMI, history of anemia) was used to compare the risk of ACM through the Day 90 visit in subjects who had ASxDVT, SxVTE or neither event. A Kaplan-Meier plot was used to display the time from the first VTE event (or time of the first ultrasound in those without an event) to ACM in the three groups. Results: In total, 7036 patients were included in the combined mITT Day 10 /mITT Day 35 analysis set. Of these, 6776 (96.3%) were included in the no VTE group, 236 (3.3%) in the ASxDVT group and 24 (0.34%) in the SxVTE group. Compared with no VTE (incidence of ACM=4.8%), both ASxDVT (11.4%, HR 2.31, 95%CI 1.52-3.51, p & lt;0.0001) and SxVTE (29.2%, HR 9.42 95%CI 4.18-21.20, p & lt;0.0001) were associated with a significant increase in ACM. The Kaplan-Meier plot shows early and continued separation in both groups compared with the group without a VTE event. Limitations: The analysis was post hoc and the groups were defined post-randomization. Adjustment was done for baseline variables that were significantly associated with ACM but may not fully compensate for potential post-randomization differences. Conclusion: These results suggest that the finding of an asymptomatic proximal DVT on routine compression ultrasonography is associated with a significantly higher ACM in acutely ill medical patients. A similar relationship was found for SxVTE and ACM, which supports the validity of ASxDVT as an indicator of clinically important disease and an appropriate endpoint for thromboprophylaxis trials in the medically ill. Disclosures Raskob: Janssen R & D, LLC: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Novartis: Consultancy; Boehringer Ingelheim: Consultancy; Eli Lilly: Consultancy; Anthos: Consultancy; Tetherex: Consultancy; Portola: Consultancy; BMS: Consultancy, Honoraria; Bayer Healthcare: Consultancy, Honoraria. Spyropoulos:Daiichi Sankyo: Consultancy; Boehringer Ingelheim: Consultancy, Research Funding; Portola: Consultancy; Bayer Healthcare: Consultancy; ATLAS (Colorado Prevention Center): Consultancy; Janssen R & D, LLC: Consultancy. Cohen:Lifeblood: Other: advisor to Lifeblood: the thrombosis charity and is the founder of the European educational charity the Coalition to Prevent Venous Thromboembolism; AbbVie: Consultancy; Aspen: Consultancy, Speakers Bureau; Bayer: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Takeda: Consultancy; Guidepoint Global: Consultancy; Boston Scientific: Consultancy; Portola: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; ONO: Consultancy, Membership on an entity's Board of Directors or advisory committees; Medscape: Consultancy, Speakers Bureau; Bristol-Myers Squibb: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Boehringer-Ingelheim: Consultancy, Speakers Bureau; McKinsey: Consultancy; Johnson and Johnson: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CSL Behring: Consultancy; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; GlaxoSmithKline: Consultancy, Speakers Bureau; GLG: Consultancy; Leo Pharma: Consultancy; Navigant: Consultancy; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sanofi: Consultancy, Membership on an entity's Board of Directors or advisory committees; Temasek Capital: Consultancy; TRN: Consultancy; UK Government Health Select Committee: Other: advised the UK Government Health Select Committee, the all-party working group on thrombosis, the Department of Health, and the NHS, on the prevention of VTE; ACI Clinical: Consultancy. Weitz:Novartis: Consultancy, Honoraria; Merck: Consultancy, Honoraria; Ionis: Consultancy, Honoraria; Daiichi-Sankyo: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Boehringer Ingelheim: Consultancy, Honoraria; Bayer Healthcare: Consultancy, Honoraria; Janssen R & D, LLC: Consultancy; Pfizer: Consultancy, Honoraria; Portola: Consultancy, Honoraria. Ageno:Sanofi: Membership on an entity's Board of Directors or advisory committees, Other: travel support; Aspen: Membership on an entity's Board of Directors or advisory committees, Other: travel support; Boehringer Ingelheim: Membership on an entity's Board of Directors or advisory committees, Other: conference and travel support; Portola: Membership on an entity's Board of Directors or advisory committees, Other: travel support; Bayer: Membership on an entity's Board of Directors or advisory committees, Other: research support,travel support ; Daiichi Sankyo: Membership on an entity's Board of Directors or advisory committees, Other: travel support; BMS Pfizer: Other: travel support. De Sanctis:Bayer US LLC: Employment, Equity Ownership. Lu:Janssen R & D, LLC: Employment, Equity Ownership. Xu:Janssen R & D, LLC: Employment, Equity Ownership. Albanese:Janssen Research and Development LLC: Employment, Equity Ownership. Sugarmann:Janssen Research and Development LLC: Employment, Equity Ownership. Lipardi:Janssen Research and Develompent: Employment, Equity Ownership. Spiro:Bayer U.S. LLC: Employment, Equity Ownership. Barnathan:Janssen Research and Development LLC: Employment, Equity Ownership. OffLabel Disclosure: Rivaroxaban is a factor Xa inhibitor and is currently under review by the FDA for thromboprophylaxis in patients with acute medical illness

Type of Medium: Online Resource

ISSN: 0006-4971 , 1528-0020

URL: Article

DOI: 10.1182/blood-2019-122934

Language: English

Publisher: American Society of Hematology

Publication Date: 2019

detail.hit.zdb_id: 1468538-3

detail.hit.zdb_id: 80069-7